J-Star

Executive Summary

J-Star Research, Inc. is a US-based contract research and manufacturing organization (CRMO) specializing in small molecule drug development, offering integrated CMC solutions from synthetic route design to cGMP clinical supply manufacturing. Founded in 1996 and headquartered in South Plainfield, New Jersey, the company operates as a subsidiary of Porton Pharma Solutions Ltd., a global CDMO. J-Star provides one-stop Chemistry, Manufacturing, and Controls services to accelerate small molecules to the clinic, serving a diverse client base of biopharmaceutical companies. With over 25 years of experience, the firm has established a strong reputation in process R&D and clinical-stage manufacturing, particularly for complex small molecules and drug delivery technologies. As a private company, J-Star benefits from Porton's broader resources and global reach, yet maintains a focused US operational footprint. The CRMO market is highly competitive, but J-Star's niche in early-stage development and its parent's financial stability position it well for steady growth. However, limited public financial disclosure and reliance on client-specific projects introduce uncertainty. The company's Phase 2 stage designation likely reflects its client projects' clinical phases rather than its own pipeline. Overall, J-Star represents a stable, specialized service provider in the small molecule CDMO space with moderate growth prospects.

Upcoming Catalysts (preview)

• Q2 2026Capacity Expansion or New Facility Announcement70% success
• Q4 2026Major Multi-Year Contract Win with a Top Biopharma50% success
• Q3 2026Parent Company Porton Pharma Solutions' Strategic Update80% success